Gastroenterology

Upadacitinib shows promising real-world effectiveness for managing moderate-to-severe Crohn disease, even in patients with prior treatment exposure.

Your daily dose of the clinical news you may have missed.

The IL-23 inhibitor is the only drug in the class available with both subcutaneous and intravenous administration options for treatment induction, according to J&J.

The impact of food elimination diets on medication previously was unknown, according to new research presented at AAAAI 2025.

The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

Researchers at Phoenix Children’s Hospital conducted one of the largest real-world clinical evaluations of the esophageal string test in children.

Your daily dose of the clinical news you may have missed.

The INTERCEPT project aims to build a blood risk score that can identify individuals with a high risk of developing Crohn disease within 5 years of initial evaluation.

Your daily dose of the clinical news you may have missed.

Marketed as Omvoh, the therapy is already approved as a first-in-class treatment for moderately to severely active ulcerative colitis.

The updated guidelines include 19 recommendations related to the diagnosis and management of eosinophilic esophagitis.

Find details on US colorectal cancer screening rates, dietary interventions for people with IBS, and research on the primary drivers of cost of IBD care.

Antiobesity medications are the next step after lifestyle interventions prove inadequate; here are the American Gastroenterological Association recommendations, at-a-glance.

Your daily dose of the clinical news you may have missed.

Results from secondary analysis suggest future work is needed to extend the prevention intervention to address additional chronic conditions and substance use.

ICYMI: A quick look at 7 key drugs FDA-approved in the second quarter for conditions commonly seen in primary care.

More participants consuming either of 2 common IBS dietary regimens experienced significant and sustained symptom relief vs those given pharmacotherapy.

Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.

Submission based on results from the phase 3 QUASAR induction study, which showed statistically significant and clinically meaningful improvements in symptoms.

Your daily dose of the clinical news you may have missed.

AAAAI 2024. Dupilumab-treated eosinophilic esophagitis in children was also more often associated with comorbid asthma, according to researchers.

Histologic inflammation was associated with reduced fertility whether IBD disease was active or quiescent in a nationwide study of Swedish women aged 15 to 44 years.

Budesonide oral suspension is the first oral therapy for EoE and represents a needed option in the category, offering flexibility for both patients and clinicians.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.